Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Curigliano

Showing results (1-10 of 190) with videos related to

Pageof 19
Sort By:
Breast Cancer Research and Treatment|February 25, 2014
Expert perspectives on biosimilar monoclonal antibodies in breast cancerJ Cortés, G Curigliano, V Diéras
ESMO Open|February 10, 2023
Targeting HER3 for cancer treatment: a new horizon for an old targetJ Uliano, C Corvaja, G Curigliano, et al.
Cancer Treatment Reviews|August 2, 2020
The global landscape of drug development for kidney cancerD Trapani, G Curigliano, Eniu Alexandru, et al.
Cancer Treatment Reviews|June 23, 2026
Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protectionD Izzo, R M Marsicano, D Trapani, et al.
British Journal of Cancer|October 17, 2003
Imatinib administration in two patients with liver metastases from GIST and severe jaundiceT De Pas, R Danesi, C Catania, et al.
Breast Cancer Research and Treatment|July 5, 2020
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancerC Criscitiello, A Vingiani, P Maisonneuve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2011
CMF revisited in the 21st centuryE Munzone, G Curigliano, H J Burstein, et al.
Drugs of Today (Barcelona, Spain : 1998)|September 29, 2021
Clinical development and current role of margetuximab for the treatment of breast cancerP Tarantino, J Uliano, S Morganti, et al.
ESMO Open|March 10, 2022
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?S Morganti, G Bianchini, A Giordano, et al.
Critical Reviews in Oncology/Hematology|March 29, 2000
Ifosfamide in the elderly: clinical considerations for a better drug managementT De Pas, G Curigliano, C Catania, et al.
Pageof 19

Showing results (1-10 of 190) with videos related to

Sort By:
Pageof 19
Breast Cancer Research and Treatment|February 25, 2014
Expert perspectives on biosimilar monoclonal antibodies in breast cancerJ Cortés, G Curigliano, V Diéras
ESMO Open|February 10, 2023
Targeting HER3 for cancer treatment: a new horizon for an old targetJ Uliano, C Corvaja, G Curigliano, et al.
Cancer Treatment Reviews|August 2, 2020
The global landscape of drug development for kidney cancerD Trapani, G Curigliano, Eniu Alexandru, et al.
Cancer Treatment Reviews|June 23, 2026
Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protectionD Izzo, R M Marsicano, D Trapani, et al.
British Journal of Cancer|October 17, 2003
Imatinib administration in two patients with liver metastases from GIST and severe jaundiceT De Pas, R Danesi, C Catania, et al.
Breast Cancer Research and Treatment|July 5, 2020
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancerC Criscitiello, A Vingiani, P Maisonneuve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2011
CMF revisited in the 21st centuryE Munzone, G Curigliano, H J Burstein, et al.
Drugs of Today (Barcelona, Spain : 1998)|September 29, 2021
Clinical development and current role of margetuximab for the treatment of breast cancerP Tarantino, J Uliano, S Morganti, et al.
ESMO Open|March 10, 2022
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?S Morganti, G Bianchini, A Giordano, et al.
Critical Reviews in Oncology/Hematology|March 29, 2000
Ifosfamide in the elderly: clinical considerations for a better drug managementT De Pas, G Curigliano, C Catania, et al.
Pageof 19